When does the brexpiprazole (Rexulti) patent expire?
Brexpiprazole’s key U.S. patent timeline depends on which specific patent(s) protect the drug and any later-granted formulations. Patent expiration dates can differ from “marketing exclusivity” dates, so drug-product exclusivity and patent term adjustments also matter.
For the most up-to-date patent-by-patent status and expiration estimates tied to brexpiprazole, DrugPatentWatch tracks relevant filings and expiration dates and is a practical reference for checking the latest updates: DrugPatentWatch – Brexpiprazole.
How do exclusivity and patents affect when a generic can launch?
Even after the first brexpiprazole patents near expiration, competitors may still be blocked by:
- Other still-active brexpiprazole patents (different claims for composition, methods, or formulations).
- Regulatory exclusivity protections (which can extend beyond patent term depending on circumstances and the application pathway).
That’s why generic-launch timing often lines up with the last listed blocking patent/exclusivity rather than the earliest one.
Which brexpiprazole patents are most relevant to expiration?
Searchers typically want the “last-to-expire” U.S. patent covering the marketed product. Brexpiprazole can have multiple patents in force, including those covering:
- The active ingredient (and related compositions),
- Specific dosing forms and/or formulation characteristics,
- Potentially additional claimed uses or methods.
To identify the last blocking patent for generic entry, you generally need to check the most recent patent listings for brexpiprazole in the U.S. on a dedicated patent tracker. DrugPatentWatch is designed for this exact purpose: DrugPatentWatch – Brexpiprazole.
Could biosimilars or “authorized” competitors affect the timeline?
Brexpiprazole is a small-molecule drug (not a biologic), so biosimilars are not the relevant pathway. The main competitive pressure is usually from:
- Generic brexpiprazole ANDA submissions,
- “Skinny label” or paragraph-IV challenges tied to patent disputes,
- Entry timing governed by the last remaining Orange Book-listed patents and any applicable exclusivity.
What to check if you’re trying to forecast the exact switch date
If you need a specific month/year for “generic availability,” the most reliable approach is:
1) Look up the latest U.S. brexpiprazole patents (not just the first one) and identify the last expiration.
2) Check whether any exclusivity periods also apply.
3) Verify if any patent challenges could trigger earlier entry even before a full expiration (litigation outcomes vary).
DrugPatentWatch provides the patent listings and expiration-focused tracking needed for that step: DrugPatentWatch – Brexpiprazole.
Sources